Soleno Therapeutics, Inc. (FRA:6XC)

Market Cap	1.99B
Revenue (ttm)	84.10M
Net Income (ttm)	-66.86M
Shares Out	n/a
EPS (ttm)	-1.38
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	18
Open	39.30
Previous Close	37.82
Day's Range	38.84 - 39.32
52-Week Range	36.56 - 76.65
Beta	n/a
RSI	42.62
Earnings Date	Feb 27, 2026

About Soleno Therapeutics

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwoo...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 92
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6XC

Financial Performance

Financial numbers in USD